ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

0GP7 Medivir Ab

41.70
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Medivir Ab LSE:0GP7 London Ordinary Share SE0020181014 MEDIVIR B ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 41.70 4,353 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 7.66M -89.32M -0.8477 -49.19 4.39B

Medivir to present at the Erik Penser Bank Company Event

21/11/2023 7:48am

PR Newswire (US)


Medivir Ab (LSE:0GP7)
Historical Stock Chart


From Dec 2022 to Dec 2024

Click Here for more Medivir Ab Charts.

STOCKHOLM, Nov. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, November 23, at 10.10 CET.

CEO Jens Lindberg will present and answer questions about the latest developments and the company's future plans. This will include, among other things, the company's proposed rights issue and how it aims to ensure the highest possible speed and momentum in the development program for fostrox with the aim of starting a pivotal phase 2b study in 2024.

The presentation is live broadcasted and can be followed at;
https://youtube.com/playlist?list=PLFeVXfrcmwBCb3H7kmr0Hmo58waVor8FZ&si=OydavujJuz5VQvoY, where it also will be available after the meeting.

The presentation will be available after the meeting on Medivirs website; www.medivir.com.

For additional information, please contact;
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com

Medivir in brief

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

The following files are available for download:

https://mb.cision.com/Main/652/3879556/2442669.pdf

Press release (PDF)

 

Cision View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-erik-penser-bank-company-event-301994503.html

SOURCE Medivir

Copyright 2023 PR Newswire

1 Year Medivir Ab Chart

1 Year Medivir Ab Chart

1 Month Medivir Ab Chart

1 Month Medivir Ab Chart

Your Recent History

Delayed Upgrade Clock